Compass Therapeutics Inc.

NASDAQ CMPX

Download Data

Compass Therapeutics Inc. Retained Earnings To Equity Ratio 1 year YoY Change (%) for the year ending December 31, 2023: -41.33%

Compass Therapeutics Inc. Retained Earnings To Equity Ratio 1 year YoY Change (%) is -41.33% for the year ending December 31, 2023, a -516.20% change year over year. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Compass Therapeutics Inc. Retained Earnings To Equity Ratio for the year ending December 31, 2022 was -1.50, a 9.93% change year over year.
  • Compass Therapeutics Inc. Retained Earnings To Equity Ratio for the year ending December 31, 2021 was -1.67, a 56.01% change year over year.
  • Compass Therapeutics Inc. Retained Earnings To Equity Ratio for the year ending December 31, 2020 was -3.79, a -468.77% change year over year.
  • Compass Therapeutics Inc. Retained Earnings To Equity Ratio for the year ending December 31, 2019 was 1.03, a -0.03% change year over year.
NASDAQ: CMPX

Compass Therapeutics Inc.

CEO Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date April 5, 2021
Location United States
Headquarters 80 Guest Street, Boston, MA, United States, 02135
Employees 32
Sector Healthcare
Industry Biotechnology
Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Similar companies

GLUE

Monte Rosa Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

TYRA

Tyra Biosciences Inc

NA

NA

VIGL

Vigil Neuroscience Inc

NA

NA

PRTC

PureTech Health PLC

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

REPL

Replimune Group Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email